TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06003738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fascia iliaca compartment block
Description: Block will be performed using an ultrasound machine with a high-frequency linear probe covered with a sterile sheath and 100 mm needle.~The patient will be positioned supine to perform the block, the skin is disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer is moved laterally until the sartorius muscle is identified. The in-plane technique will be used, and the tip of the needle will be inserted between the fascia iliaca and iliopsoas muscle. a syringe containing 15ml of 0.25% bupivacaine will be injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pericapsular nerve block
Description: The block will be performed using the curvilinear low-frequency ultrasound probe to be placed over the line parallel to the inguinal ligament then It will be rotated 45◦ to identify the anterior inferior iliac spine, the iliopubic eminence, and the psoas tendon. A 22-gauge, 80 mm echogenic needle will be inserted in an in-plane approach to place the tip in the musculofascial plane between the pubic ramus posteriorly and the psoas tendon anteriorly a syringe containing 15ml of 0.25% bupivacaine will be injected .
Study: NCT05555225

Intervention type: OTHER
Intervention: Methylome
Description: Epigenetic study : analysis of DNA methylation

Intervention type: OTHER
Intervention: Methylome
Description: Epigenetic study : analysis of DNA methylation

Intervention type: OTHER
Intervention: Methylome
Description: Epigenetic study : analysis of DNA methylation
Study: NCT05672017

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Instructions
Description: Dietary Instructions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Instructions
Description: Dietary Instructions

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Instructions
Description: Dietary Instructions
Study: NCT06003738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: palcebo fascia iliaca compartment block
Description: Block will be performed using an ultrasound machine with a high-frequency linear probe covered with a sterile sheath and 100 mm needle.~The patient will be positioned supine to perform the block, the skin is disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer is moved laterally until the sartorius muscle is identified. The in-plane technique will be used, and the tip of the needle will be inserted between the fascia iliaca and iliopsoas muscle. a syringe containing 15ml of normal saline will be injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: palcebo pericapsular nerve block
Description: The block will be performed using the curvilinear low-frequency ultrasound probe to be placed over the line parallel to the inguinal ligament then It will be rotated 45◦ to identify the anterior inferior iliac spine, the iliopubic eminence, and the psoas tendon. A 22-gauge, 80 mm echogenic needle will be inserted in an in-plane approach to place the tip in the musculofascial plane between the pubic ramus posteriorly and the psoas tendon anteriorly a syringe containing 15ml of normal saline will be injected .
Study: NCT06059690

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: pH Measurement of in vivo tissue
Description: The investigator will identify multiple (2-5) 5-8mm diameter spherical targets on GI maps for use in stereotactic pH measurement and biopsy acquisition. All biopsies are acquired for standard of care and according to standard of care procedures. A 13-gauge biopsy needle and plastic cannula will be inserted into the region of interest identified on MRI and PET. The biopsy needle will be removed, and the Softcell® pH probe, consisting of a 1.8mm diameter high quality glass tip and 1.6m long wire, will be guided down the cannula and inserted at least 15mm into the tissue. Recordings will be made for 1 minute to stabilize the reading, then the pH probe will be removed from the region of interest and placed into a saline vial for the next biopsy target. After the pH probe is removed, the biopsy needle will be placed into the cannula and standard-of-care biopsy tissue will be obtained from the same area where pH measurements were recorded.
Study: NCT06452199

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B. infantis
Description: 1000 newborn children are randomized 50/50 to receive either B. infanits or placebo in a dietary supplement, for daily oral administration in three weeks from 7 days of age.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical looking placebo (without any probiotics/B. infantis) for double-blinded daily oral administration in three weeks from 7 days of age.
Study: NCT05893147

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: De-escalation VS No De-escalation
Description: No de-escalation group: continue to receive the same antibiotic that was started initially (as long as it is confirmed to be effective based on the blood culture sensitivity result)~De-escalation group: switched to narrower spectrum antibiotic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral beta-lactams VS non beta-lactams
Description: Beta-lactam antibiotic: This can be ciprofloxacin, moxifloxacin, levofloxacin or trimethoprim-sulfamethoxazole.~Non beta-lactam antibiotic: This can be, but not limited to, amoxicillin, amoxicillin-clavulanate, cephalexin, cefadroxil, or cefixime.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Central vascular catheter retention VS Central vascular catheter replacement
Description: Central vascular catheter replacement: the catheter will be changed by the treating team as soon as possible and within a maximum of 72 hours from blood culture finalization~Central vascular catheter retention: the catheter will not be changed and will be retained until it is no longer needed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cephalosporin VS Carbapenem for low risk AmpC organisms
Description: Cephalosporin (ceftriaxone) at standard doses~Carbapenem (like Meropenem, Ertapenem etc) at standard doses

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine follow-up blood culture VS No routine follow-up blood culture
Description: Routine follow-up blood culture: routine repeat blood collection 4 days from the index blood collection with positive bacteria.~No follow-up blood culture: no routine repeat blood collection 4 days from the index blood collection with positive bacteria
Study: NCT06017089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-based Advisor system
Description: Tandem t:slim X2 with Control-IQ and t:connect mobile application and Dexcom G6 or G7 system, connected to UVA cloud-based Physician Dashboard with insulin pump parameters driven by an AI-based Advisor system.
Study: NCT05637775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG-based BCI system for (hands) Motor Imagery training
Description: For the purposes of this study we adapted an available BCI-supported motor imagery (MI) training station, equipped with a computer, a commercial wireless Electroencephalography (EEG)/ Electromyography (EMG) system, a screen for therapist feedback and a screen for the real-time ecological feedback to patient - a custom software program that provides a for (personalized) visual representation of the patient's own hands. This software allows the therapists to create an artificial reproduction of patient's hands/forearms by adjusting a digitally created image in shape, size, skin colour and orientation to match as much as possible the real patient hands/forearms. Training consists of the MI tasks of both hands, grasping or finger extension in separate runs. The trial length will include a constant baseline period of 4 sec and a task period of maximally 10 sec for BCI intervention group. Each training session will consist of 4 runs (20 trials each).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control - MI intervention
Description: Training consists of MI tasks of both hands, grasping or finger extension in separate runs. MI training will be delivered with a dose/setting regimen equivalent to EXP intervention. The trial length will include a constant baseline period of 4 sec and a task period of maximally 4 sec. Each training session will consist of 4 runs (20 trials each).
Study: NCT06061081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH3739937
Description: VH3739937 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT06515483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brushing and Flossing of teeth
Description: 32 subjects will be instructed to clean their teeth daily using only the provided toothbrush with an assigned ADA-accepted fluoride dentifrice. Subjects in the experimental group will brush and floss with the provided stretchable loop floss at least twice a day. To assess compliance, each subject will be asked to fill out a diary every time they brush/floss. On day 15 (+/- 2) day of product use, subjects will receive a phone call from the study coordinator or designee to assess brushing/flossing compliance. At day 30 (+/- 2), study hygiene and gum chewing restrictions as well as eating restriction will apply, and the efficacy assessments will be repeated, subjects will be dismissed, and the study will finish.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Brushing Only
Description: 32 subjects will be instructed to clean their teeth daily using only the provided toothbrush with an assigned ADA-accepted fluoride dentifrice. Subjects assigned to the control group will brush their teeth at least twice a day only. On day 15 (+/- 2) day of product use, subjects will receive a phone call from the study coordinator or designee to assess brushing/flossing compliance. At day 30 (+/- 2), study hygiene and gum chewing restrictions as well as eating restriction will apply, and the efficacy assessments will be repeated, subjects will be dismissed, and the study will finish.
Study: NCT06018558

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OCU410
Description: Subretinal administration of OCU410
Study: NCT05671744

Intervention type: OTHER
Group type: OTHER
Intervention: Cell-based non-invasive prenatal testing
Description: Blood sampling
Study: NCT06018558

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OCU410
Description: Subretinal administration of OCU410

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OCU410
Description: Subretinal administration of OCU410

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OCU410
Description: Subretinal administration of OCU410

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OCU410
Description: Subretinal administration of OCU410
Study: NCT05657990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin 0.4 mg one time daily after a meal for seven days prior to surgery. Post-surgery, an ultrasound of the bladder will be completed approximately six hours after surgery to assess the bladder. If the bladder ultrasound shows more than 400 cc of urine in the bladder, or if the study subject passes urine on his own and there is more than 100cc or less than 400 cc of urine left in the bladder, he will be encouraged to try to pass urine. Study subject will be monitored for two additional hours. If a study subject is unable to pass urine at this time or the bladder has 400 cc or more of urine left in it, he will have an intermittent catheter (in and out) to drain urine. If the bladder has greater than 500 cc (which is approximately 16 and two-thirds ounces) per catheterization for more than 24 hours, and the study subject cannot pass urine, an indwelling catheter may be considered.
Study: NCT05845567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat
Description: ITF2357 Givinostat 10mg/mL. Dose: 10 mg/mL; Dosage form: oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin 500 mg immediate-release oral film-coated tablet (Klacid®) was administered twice a day, in the morning and in the evening.
Study: NCT06648252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healing Minds Biofeedback and Breathing Practices Intervention
Description: The study participant will attend ten weekly Healing Minds sessions at the Hoskinson Health and Wellness Clinic. The parent (s) or guardian will accompany the study participant and follow along with the cues during the weekly session. Each session will be approximately 60 minutes. The principal investigator/pediatrician or trained and certified health care or research staff member will deliver the intervention. Biofeedback will be implemented based on the Heart Math Protocol. Breathing practices will include a variety of yoga and qi gong techniques.
Study: NCT06648018

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional information
Description: Written nutritional information about food with high content of iron.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron-succinate
Description: 100 mg of Iron-succinate per day.
Study: NCT05098119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab, Nab-paclitaxel, Carboplatin
Description: Neoadjuvant Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Adjuvant Therapy
Study: NCT06341543

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Quantiferon CMV (assay that determine the presence of CMV-specific T lymphocytes).
Description: The QF-CMV will be performed in all participants.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantiferon CMV (assay that determine the presence of CMV-specific T lymphocytes).
Description: The QF-CMV will be performed in all participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication of the result of the QF-CMV to the clinician in charge
Description: The result of the CMV-QF will be communicated to the clinician in charge only for the patients randomised in the group communication of the QF-CMV result to the clinician in charge.
Study: NCT05763875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: 284 mg (equivalent to 300 mg inclisiran sodium) subcutaneous injection given on Day 1 and Day 90

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: 10 mg over-encapsulated tablet taken once a day from Day 1 through Day 149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching Placebo for Inclisiran
Description: 0mg placebo injection solution for subcutaneous injection on Day 1 and Day 90

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for Inclisiran
Description: 0mg placebo injection solution for subcutaneous injection on Day 1 and Day 90

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo for Ezetimibe
Description: 0mg over-encapsulated placebo tablet taken once a day from Day 1 through Day 149

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for Ezetimibe
Description: 0mg over-encapsulated placebo tablet taken once a day from Day 1 through Day 149
Study: NCT05028075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cobalt +
Description: Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity) at enrollment; 0 months and then again at 6 months. The primary endpoint is assessed at 6 months. A secondary endpoint of persistence of effect is measured 3 months later-9 months post initiation. The intervention group receives usual Cobalt plus: 1) monthly automated text messaging reminders and links to Cobalt resources 2) intermittent mental health assessments which triage individuals to an appointment based on their results.
Study: NCT05773651

Intervention type: OTHER
Intervention: Data collection
Description: The data collection includes, among other things: Diagnosis of the rare tumor (pathological findings/ reference pathological findings), full name, birth date, gender, clinical registry inclusion and exclusion criteria met - yes / no, signed declaration of consent-yes / no, if yes: date of signature
Study: NCT06575179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine low-dose
Description: The low-dose dexmedetomidine group received a 75 μg/h loading dose over 15 minutes, followed by 60 μg/h maintenance infusion intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: The control group received volume-matched 0.9% saline infusions at identical rates.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine high-dose
Description: The high-dose dexmedetomidine group received a 150 μg/h loading dose over 15 minutes, followed by 120 μg/h maintenance infusion intravenously.
Study: NCT06243952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARC-BSI Lumbar system
Description: Implantation of a 64 channel - ECoG array over the sensory motor cortex of the lower limbs, combined with an implantation of 16 channel spinal cord stimulation system over the lumbar region. The decoded motor intentions are driving the implanted spinal cord stimulation system. Brain-controlled spinal cord stimulation is used for training and rehabilitation to recover voluntary movements.
Study: NCT05200013

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAT7104
Description: Symmetric IgG-like AntiPD-L1/CD47 Bispecific Antibody Solution for Injection BAT7104 injection available in 100 mg/2 mL (50 mg/mL) dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAT7104
Description: Symmetric IgG-like AntiPD-L1/CD47 Bispecific Antibody Solution for Injection BAT7104 injection available in 100 mg/2 mL (50 mg/mL) dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAT7104
Description: Symmetric IgG-like AntiPD-L1/CD47 Bispecific Antibody Solution for Injection BAT7104 injection available in 100 mg/2 mL (50 mg/mL) dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAT7104
Description: Symmetric IgG-like AntiPD-L1/CD47 Bispecific Antibody Solution for Injection BAT7104 injection available in 100 mg/2 mL (50 mg/mL) dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAT7104
Description: Symmetric IgG-like AntiPD-L1/CD47 Bispecific Antibody Solution for Injection BAT7104 injection available in 100 mg/2 mL (50 mg/mL) dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAT7104
Description: Symmetric IgG-like AntiPD-L1/CD47 Bispecific Antibody Solution for Injection BAT7104 injection available in 100 mg/2 mL (50 mg/mL) dosage
Study: NCT06649513

Intervention type: DIAGNOSTIC_TEST
Intervention: eye drops (Tropicamid)
Description: Mydriatic + cycloplegic eye drops are given to measure refractive error and to image the full retina.
Study: NCT06221488

Intervention type: DIAGNOSTIC_TEST
Intervention: TB infection testing
Description: Diagnostic testing with existing and novel tests to evaluate for TB infection and disease
Study: NCT05122910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management and Resilience Training - Moral Resilience (SMART-MR) program
Description: All participants will attend an initial 2.5 hour workshop and a 1-hour follow-up workshop. The workshop will include general resilience strategies with a focus on the moral/ethical dimensions of clinical practice to offer participants specific skills to address ethical challenges. In addition to the workshops, there will be follow-up supplemental resources.
Study: NCT05077176

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac
Description: One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Turkovac
Description: One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
Study: NCT05433909

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood, fecal, vaginal and endometrial liquid samples
Description: During the surgical pre-hospitalization, eligible patients who accept participation in the study will undergo a blood sample and collection of stool samples.~Before surgery, after anesthesia, they will undergo a vaginal swab and endometrial fluid sampling.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood, fecal, vaginal and endometrial liquid samples
Description: During the surgical pre-hospitalization, eligible patients who accept participation in the study will undergo a blood sample and collection of stool samples.~Before surgery, after anesthesia, they will undergo a vaginal swab and endometrial fluid sampling.
Study: NCT05470621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PlayOn! playground curriculum
Description: A staff and student training to implement a playground curriculum in after-school and recess settings
Study: NCT04998721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships-Brief
Description: A brief version of the evidence based Promoting First Relationships (PFR) parenting intervention in which a parent is supported in appropriate interpretation of infant cues and in developing skills to effectively parent an infant. Sessions consist of reflective content (observing and reflecting back to the mother on patterns of dyadic interaction) and informational handouts. Reflective content will be delivered in person, and text messaging protocol will deliver informational content at developmentally appropriate times. PFR-B sessions are delivered in primary care settings beginning in the third trimester and continuing postpartum.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Perinatal Collaborative Care
Description: Collaborative Care (CC) is an integrated care model that is effective in the treatment of perinatal depression. CC provides team driven, population focused, measurement guided and evidence based care to improve access and outcomes, control costs, and increase patient satisfaction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perinatal Collaborative Care
Description: Collaborative Care (CC) is an integrated care model that is effective in the treatment of perinatal depression. CC provides team driven, population focused, measurement guided and evidence based care to improve access and outcomes, control costs, and increase patient satisfaction.